Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 5/20 | 0.60 |
| ▸ | DRD2 | P14416 | 4/20 | 0.60 |
| ▸ | DRD5 | P21918 | 4/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 2/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5658186 | 0.99 | DRD3 (0.59) | DRD3DRD2DRD5HTR1AACHE | |
| SCHEMBL5658279 | 0.97 | DRD2 (0.64) | DRD3DRD2DRD5HTR1AACHE | |
| Hydrochloric Acid SCHEMBL5656043 | 0.96 | DRD2 (0.62) | DRD3DRD2DRD5HTR1AACHE | |
| SCHEMBL5659084 | 0.92 | ACHE (0.62) | DRD3DRD2DRD5HTR1AACHE | |
| Hydrochloric Acid SCHEMBL5658146 | 0.91 | ACHE (0.61) | DRD3DRD2DRD5HTR1AACHE | |
| SCHEMBL5660496 | 0.87 | HTR1A (0.62) | DRD3DRD2DRD5HTR1AACHE | |
| SCHEMBL5655963 | 0.85 | CHRM1 (0.67) | DRD3DRD2 | |
| SCHEMBL5660624 | 0.84 | HTR1A (0.49) | DRD3DRD2DRD5HTR1AACHE | |
| SCHEMBL19028093 | 0.83 | HTR1A (0.58) | DRD3DRD2DRD5HTR1AACHE | |
| SCHEMBL29802804 | 0.82 | DRD3 (0.67) | DRD3DRD2DRD5HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | DRD3 395/4885DRD2 402/4885DRD5 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.